Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCCJune 23, 2022Hepatocellular Carcinoma
HCC with Child-Pugh B cirrhosis: Nivolumab a promising first-line systemic treatment optionJune 23, 2022Hepatocellular Carcinoma
Preoperative ratio of creatinine and cystatin C estimated glomerular filtration rates predicts survival outcomes after hepatic resection for HCCJune 23, 2022Hepatocellular Carcinoma
C reactive protein to albumin ratio predicts survival outcomes in lenvatinib-treated patients with unresectable HCCJune 23, 2022Hepatocellular Carcinoma
Microwave ablation bridges patients with HCC to liver transplantJune 23, 2022Hepatocellular Carcinoma
Pediatric HCC: Histologic subtypes demonstrate distinct clinical patternsJune 23, 2022Hepatocellular Carcinoma
Radiation segmentectomy: A promising treatment option for well-selected patients with HCCJune 23, 2022Hepatocellular Carcinoma
Commentary: Immunotherapy Improves Outcomes in Hepatocellular Cancer, June 2022May 25, 2022Hepatocellular Carcinoma
TIPS plus sequential systemic therapy shows promise in advanced HCC with tumor thrombus-related SPHMay 17, 2022Hepatocellular Carcinoma
HCC incidence after successful DAA therapy for hepatitis C varies with cirrhosis statusMay 17, 2022Hepatocellular Carcinoma
Efficacy and safety of tumor vaccines in HCC: Lessons from two decades of researchMay 17, 2022Hepatocellular Carcinoma
Advanced HCC: Lenvatinib plus nivolumab yields promising results in real-world May 17, 2022Hepatocellular Carcinoma
Laparoscopic anatomic hepatectomy achieves better follow-up outcomes than non-anatomical hepatectomy in HCCMay 17, 2022Hepatocellular Carcinoma
